Hitachi Chemical Co., Ltd. and MD Anderson enter into strategic alliance
Hitachi Chemical Co., Ltd. and The University of Texas MD Anderson Cancer Center have entered into a four-year strategic alliance funded by Hitachi to help develop and evaluate the company’s Micro Cavity Array (MCA) Circulating Tumor Cell (CTC) system for the isolation of CTC that can be subjected to downstream molecular analyses.
CTCs offer an alternative to more invasive procedures for assessing tumors, and have proven...
Making Cancer History® Seminar returns to Aspen July 22
The University of Texas MD Anderson Cancer Center heads to Aspen this summer for its 18th annual Making Cancer History® seminar. The free...
Novel gene-hunting method implicates new culprit in pancreatic cancer
Using an innovative approach to identify a cancer’s genetic vulnerabilities by more swiftly analyzing human tumors transplanted into mice,...
MD Anderson to host a national Cancer Moonshot Summit event June 29
The University of Texas MD Anderson Cancer Center will join institutions across the country in the inaugural national Cancer Moonshot Summit, convened at the request of Vice President Joe Biden, on June 29.
MD Anderson will host a free breakfast event in conjunction with the national summit, which is designed to bring together patients and survivors, researchers, physicians, advocates, philanthropists and data and tech experts...
Shorter radiation course recommended for early-stage breast cancer patients
Early-stage breast cancer patients receiving a shorter course of whole breast radiation with higher radiation doses per fraction reported...
Antibody-based drug helps “bridge” leukemia patients to curative treatment
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic...
MD Anderson and Bristol-Myers Squibb announce new research collaboration in immuno-oncology focused on lung cancer
HOUSTON and NEW YORK -- Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a new clinical...
Progression-free survival triples in select metastatic lung cancer patients with surgery or radiation after standard chemotherapy
ABSTRACT: 9004
Lung cancer patients with oligometastases, defined as three or fewer sites of metastasis, may benefit from aggressive...
MD Anderson researchers highlight advances in gynecologic cancer treatments
ABSTRACTS: 5506, 5502, 1506
Advances that could change gynecologic cancer standard–of-care treatments are the centerpiece of...
Nivolumab immunotherapy helps patients with advanced bladder cancer
ABSTRACT: 4501
The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder...
Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer
ABSTRACT: 3503
In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University...
MD Anderson study identifies significant cost differences between breast cancer chemotherapy regimens
ABSTRACT: 6519
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness...